Cover Image
市場調查報告書

氣喘市場分析、預測

Asthma Forecast and Market Analysis to 2024

出版商 Datamonitor Healthcare 商品編碼 618931
出版日期 內容資訊 英文 680 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
氣喘市場分析、預測 Asthma Forecast and Market Analysis to 2024
出版日期: 2018年02月16日 內容資訊: 英文 680 Pages
簡介

本報告提供氣喘其治療藥的市場調查,疾病的背景,目前治療選擇,診斷及處方趨勢,學名藥的影響,未滿足需求,美國、日本、歐盟5國的銷售情況與預測,已上市藥物的簡介,開發平台趨勢,各地區的藥價設定、償付、存取趨勢等彙整資料。

預測:美國、日本、歐盟5國的氣喘

  • 摘要整理
  • 預測更新
  • 市場動態
  • 預測、未來趨勢
  • 市場定義、調查手法
  • 文獻
    • 產品簡介:ADVAIR
    • 產品簡介:BREO ELLIPTA
    • 產品簡介:CINQAIR
    • 產品簡介:DULERA
    • 產品簡介 (後期):DUPIXENT
    • 產品簡介:FASENRA
    • 產品簡介:FLUTIFORM
    • 產品簡介:NUCALA
    • 產品簡介 (後期):QVM149
    • 產品簡介:SINGULAIR
    • 產品簡介:SPIRIVA
    • 產品簡介:SYMBICORT
    • 產品簡介 (後期):TRELEGY ELLIPTA
    • 產品簡介:XOLAIR

治療

  • 摘要整理
  • 疾病定義、診斷
  • 患者區分
  • 目前治療選擇
  • 處方趨勢
  • 學名藥的影響
  • 未滿足需求

流行病學

  • 摘要整理
  • 疾病背景
  • 調查手法
  • 預測
  • 流行病學者的考察
  • 優勢、規定
  • 文獻
  • 附錄:其他資訊來源

已上市藥物

  • 摘要整理
  • 產品概要
    • 產品簡介:ADVAIR
    • 產品簡介:BREO ELLIPTA
    • 產品簡介:CINQAIR
    • 產品簡介:DULERA
    • 產品簡介:FASENRA
    • 產品簡介:FLUTIFORM
    • 產品簡介:NUCALA
    • 產品簡介:SINGULAIR
    • 產品簡介:SPIRIVA
    • 產品簡介:SYMBICORT
    • 產品簡介:XOLAIR

藥價設定、償付、存取

  • 摘要整理
  • 市場背景
  • 全球保險者的考察
  • 美國的藥價設定
  • 美國的保險者的考察
  • 美國的償付
  • 日本
  • EU主要5個國家藥價設定
  • EU主要5個國家的保險者的考察
  • EU主要5個國家非專利ICS/LABA吸入劑
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 調查手法

開發平台:氣喘

  • 摘要整理
  • 臨床實驗平台 概要
  • 產品簡介 (後期):DUPIXENT
  • 產品簡介 (後期):QVM149
  • 產品簡介 (後期):TRELEGY ELLIPTA
目錄
Product Code: DMKC5962

Disease Overview:

Asthma is a chronic respiratory disease characterized by recurrent breathlessness and wheezing, which occur in acute events known as attacks. These attacks can vary significantly in frequency and severity, and consist of swelling of the lining of the bronchial tubes, which narrows airways and results in a reduction of airflow into and out of the lungs. Collaborators of the Global Initiative for Asthma believe that as many as 300 million people worldwide are greatly impacted by asthma in their daily lives, whether through asthma symptoms not allowing them to undertake simple day-to-day activities or through being unable to complete assigned tasks at work.

Recent events and opinion:

  • Biologic therapies will drive growth in the asthma market despite generic erosion of key ICS/LABA combinations.
  • Datamonitor Healthcare's survey of 221 physicians sheds light on treatment patterns and prescribing influences.
  • There were an estimated 51.3 million diagnosed prevalent cases in 2016; this is predicted to rise due to population growth.
  • Competition for eosinophilic asthma is intensifying with the recent approval of Fasenra, the third-to-market IL-5 inhibitor.
  • Bolstered by strong clinical data, Dupixent is poised to have a large impact on the biologic therapies market.
  • Payers' fear of the budget impact of newly approved IL-5 inhibitors will prompt tighter access control.

TABLE OF CONTENTS

(Forecast, Treatment, Epidemiology and Pipeline Datapacks included)

FORECAST: ASTHMA IN THE US, JAPAN, AND 5EU (Published on 16 February 2018)

  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
    • PRODUCT PROFILE: ADVAIR
    • PRODUCT PROFILE: BREO ELLIPTA
    • PRODUCT PROFILE: CINQAIR
    • PRODUCT PROFILE: DULERA
    • PRODUCT PROFILE (LATE STAGE): DUPIXENT
    • PRODUCT PROFILE: FASENRA
    • PRODUCT PROFILE: FLUTIFORM
    • PRODUCT PROFILE: NUCALA
    • PRODUCT PROFILE (LATE STAGE): QVM149
    • PRODUCT PROFILE: SINGULAIR
    • PRODUCT PROFILE: SPIRIVA
    • PRODUCT PROFILE: SYMBICORT
    • PRODUCT PROFILE (LATE STAGE): TRELEGY ELLIPTA
    • PRODUCT PROFILE: XOLAIR

TREATMENT: ASTHMA (Published on 19 February 2018)

  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • COUNTRY TREATMENT TREES
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • IMPACT OF GENERICS
  • UNMET NEEDS IN ASTHMA

EPIDEMIOLOGY: ASTHMA (Published on 05 January 2018)

  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: ASTHMA (Published on 16 February 2018)

  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
    • PRODUCT PROFILE: ADVAIR
    • PRODUCT PROFILE: BREO ELLIPTA
    • PRODUCT PROFILE: CINQAIR
    • PRODUCT PROFILE: DULERA
    • PRODUCT PROFILE: FASENRA
    • PRODUCT PROFILE: FLUTIFORM
    • PRODUCT PROFILE: NUCALA
    • PRODUCT PROFILE: SINGULAIR
    • PRODUCT PROFILE: SPIRIVA
    • PRODUCT PROFILE: SYMBICORT
    • PRODUCT PROFILE: XOLAIR

ASTHMA PRICING, REIMBURSEMENT, AND ACCESS (Published on 05 May 2016)

  • EXECUTIVE SUMMARY
  • MARKET CONTEXT
  • GLOBAL PAYER INSIGHTS
  • US PRICING
  • US PAYER INSIGHTS
  • US REIMBURSEMENT
  • JAPAN
  • FIVE MAJOR EU MARKETS PRICING
  • FIVE MAJOR EU MARKETS PAYER INSIGHTS
  • GENERIC ICS/LABA INHALERS IN THE FIVE MAJOR EU MARKETS
  • FRANCE
  • GERMANY
  • ITALY
  • SPAIN
  • UK
  • METHODOLOGY

PIPELINE: ASTHMA (Published on 16 February 2018)

  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • PRODUCT PROFILE (LATE STAGE): DUPIXENT
  • PRODUCT PROFILE (LATE STAGE): QVM149
  • PRODUCT PROFILE (LATE STAGE): TRELEGY ELLIPTA

LIST OF FIGURES

  • Figure 1: Asthma - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for asthma
  • Figure 3: Asthma sales across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 4: Asthma sales across the US, Japan, and five major EU markets, by class, 2017-26
  • Figure 5: Sales of IL inhibitors across the US, Japan, and five major EU markets, by drug, 2017-26
  • Figure 6: Sales of ICS/LABA therapies across the US, Japan, and five major EU markets, by drug, 2017-26
  • Figure 7: Triple therapy sales across the US, Japan, and five major EU markets, by drug, 2017-26
  • Figure 8: Patient-based asthma forecast methodology
  • Figure 9: Price sources and calculations, by country
  • Figure 10: Advair for asthma - SWOT analysis
  • Figure 11: Datamonitor Healthcare's drug assessment summary of Advair in asthma
  • Figure 12: Datamonitor Healthcare's drug assessment summary of Advair in asthma
  • Figure 13: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 14: Breo Ellipta for asthma - SWOT analysis
  • Figure 15: Datamonitor Healthcare's drug assessment summary of Breo Ellipta in asthma
  • Figure 16: Datamonitor Healthcare's drug assessment summary of Breo Ellipta in asthma
  • Figure 17: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 18: Cinqair for asthma - SWOT analysis
  • Figure 19: Datamonitor Healthcare's drug assessment summary of Cinqair in asthma
  • Figure 20: Datamonitor Healthcare's drug assessment summary of Cinqair in asthma
  • Figure 21: Cinqair sales for asthma across the US and five major EU markets, by country, 2017-26
  • Figure 22: Dulera for asthma - SWOT analysis
  • Figure 23: Datamonitor Healthcare's drug assessment summary of Dulera in asthma
  • Figure 24: Datamonitor Healthcare's drug assessment summary of Dulera in asthma
  • Figure 25: Dulera sales for asthma in the US, 2017-26
  • Figure 26: Dupixent for asthma - SWOT analysis
  • Figure 27: Datamonitor Healthcare's drug assessment summary of Dupixent in asthma
  • Figure 28: Datamonitor Healthcare's drug assessment summary of Dupixent in asthma
  • Figure 29: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 30: Fasenra for asthma - SWOT analysis
  • Figure 31: Datamonitor Healthcare's drug assessment summary of Fasenra in asthma
  • Figure 32: Datamonitor Healthcare's drug assessment summary of Fasenra in asthma
  • Figure 33: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 34: Flutiform for asthma - SWOT analysis
  • Figure 35: Datamonitor Healthcare's drug assessment summary of Flutiform in asthma
  • Figure 36: Datamonitor Healthcare's drug assessment summary of Flutiform in asthma
  • Figure 37: Flutiform sales for asthma across Japan and the five major EU markets, by country, 2017-26
  • Figure 38: Nucala for asthma - SWOT analysis
  • Figure 39: Datamonitor Healthcare's drug assessment summary of Nucala in asthma
  • Figure 40: Datamonitor Healthcare's drug assessment summary of Nucala in asthma
  • Figure 41: Nucala sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 42: QVM149 for asthma - SWOT analysis
  • Figure 43: Datamonitor Healthcare's drug assessment summary of QVM149 in asthma
  • Figure 44: Datamonitor Healthcare's drug assessment summary of QVM149 in asthma
  • Figure 45: QVM149 sales for asthma across Japan and the five major EU markets, by country, 2017-26
  • Figure 46: Singulair for asthma - SWOT analysis
  • Figure 47: Datamonitor Healthcare's drug assessment summary of Singulair in asthma
  • Figure 48: Datamonitor Healthcare's drug assessment summary of Singulair in asthma
  • Figure 49: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 50: Spiriva for asthma - SWOT analysis
  • Figure 51: Datamonitor Healthcare's drug assessment summary of Spiriva in asthma
  • Figure 52: Datamonitor Healthcare's drug assessment summary of Spiriva in asthma
  • Figure 53: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 54: Symbicort for asthma - SWOT analysis
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Symbicort in asthma
  • Figure 56: Datamonitor Healthcare's drug assessment summary of Symbicort in asthma
  • Figure 57: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 58: Trelegy Ellipta for asthma - SWOT analysis
  • Figure 59: Datamonitor Healthcare's drug assessment summary of Trelegy Ellipta in asthma
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Trelegy Ellipta in asthma
  • Figure 61: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 62: Xolair for asthma - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Xolair in asthma
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Xolair in asthma
  • Figure 65: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 66: Percentage of asthma patients remaining undiagnosed, by severity and country (%)
  • Figure 67: Severity of diagnosed asthma patients in the US, Japan, and five major EU markets, by country (%), 2017
  • Figure 68: Trend in 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 69: Absolute change in 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 70: Advair for asthma - SWOT analysis
  • Figure 71: Datamonitor Healthcare's drug assessment summary of Advair in asthma
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Advair in asthma
  • Figure 73: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 74: Breo Ellipta for asthma - SWOT analysis
  • Figure 75: Datamonitor Healthcare's drug assessment summary of Breo Ellipta in asthma
  • Figure 76: Datamonitor Healthcare's drug assessment summary of Breo Ellipta in asthma
  • Figure 77: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 78: Cinqair for asthma - SWOT analysis
  • Figure 79: Datamonitor Healthcare's drug assessment summary of Cinqair in asthma
  • Figure 80: Datamonitor Healthcare's drug assessment summary of Cinqair in asthma
  • Figure 81: Cinqair sales for asthma across the US and five major EU markets, by country, 2017-26
  • Figure 82: Dulera for asthma - SWOT analysis
  • Figure 83: Datamonitor Healthcare's drug assessment summary of Dulera in asthma
  • Figure 84: Datamonitor Healthcare's drug assessment summary of Dulera in asthma
  • Figure 85: Dulera sales for asthma in the US, 2017-26
  • Figure 86: Fasenra for asthma - SWOT analysis
  • Figure 87: Datamonitor Healthcare's drug assessment summary of Fasenra in asthma
  • Figure 88: Datamonitor Healthcare's drug assessment summary of Fasenra in asthma
  • Figure 89: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 90: Flutiform for asthma - SWOT analysis
  • Figure 91: Datamonitor Healthcare's drug assessment summary of Flutiform in asthma
  • Figure 92: Datamonitor Healthcare's drug assessment summary of Flutiform in asthma
  • Figure 93: Flutiform sales for asthma across Japan and the five major EU markets, by country, 2017-26
  • Figure 94: Nucala for asthma - SWOT analysis
  • Figure 95: Datamonitor Healthcare's drug assessment summary of Nucala in asthma
  • Figure 96: Datamonitor Healthcare's drug assessment summary of Nucala in asthma
  • Figure 97: Nucala sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 98: Singulair for asthma - SWOT analysis
  • Figure 99: Datamonitor Healthcare's drug assessment summary of Singulair in asthma
  • Figure 100: Datamonitor Healthcare's drug assessment summary of Singulair in asthma
  • Figure 101: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 102: Spiriva for asthma - SWOT analysis
  • Figure 103: Datamonitor Healthcare's drug assessment summary of Spiriva in asthma
  • Figure 104: Datamonitor Healthcare's drug assessment summary of Spiriva in asthma
  • Figure 105: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 106: Symbicort for asthma - SWOT analysis
  • Figure 107: Datamonitor Healthcare's drug assessment summary of Symbicort in asthma
  • Figure 108: Datamonitor Healthcare's drug assessment summary of Symbicort in asthma
  • Figure 109: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 110: Xolair for asthma - SWOT analysis
  • Figure 111: Datamonitor Healthcare's drug assessment summary of Xolair in asthma
  • Figure 112: Datamonitor Healthcare's drug assessment summary of Xolair in asthma
  • Figure 113: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 114: Dupixent for asthma - SWOT analysis
  • Figure 115: Datamonitor Healthcare's drug assessment summary of Dupixent in asthma
  • Figure 116: Datamonitor Healthcare's drug assessment summary of Dupixent in asthma
  • Figure 117: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 118: QVM149 for asthma - SWOT analysis
  • Figure 119: Datamonitor Healthcare's drug assessment summary of QVM149 in asthma
  • Figure 120: Datamonitor Healthcare's drug assessment summary of QVM149 in asthma
  • Figure 121: QVM149 sales for asthma across Japan and the five major EU markets, by country, 2017-26
  • Figure 122: Trelegy Ellipta for asthma - SWOT analysis
  • Figure 123: Datamonitor Healthcare's drug assessment summary of Trelegy Ellipta in asthma
  • Figure 124: Datamonitor Healthcare's drug assessment summary of Trelegy Ellipta in asthma
  • Figure 125: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Table 1: Exchange rates used for calculating prices
  • Table 2: Primary care physicians and pulmonologists surveyed for the asthma primary research study, 2017
  • Table 3: Advair drug profile
  • Table 4: Advair Diskus pivotal trial data in asthma
  • Table 5: Advair HFA pivotal trial data in asthma
  • Table 6: Advair late-phase trial data in asthma
  • Table 7: Advair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 8: Breo Ellipta drug profile
  • Table 9: Breo Ellipta pivotal trial data in asthma
  • Table 10: Breo Ellipta late-phase trial data in asthma
  • Table 11: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 12: Cinqair drug profile
  • Table 13: Cinqair pivotal Phase III data in asthma
  • Table 14: Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017-26
  • Table 15: Dulera drug profile
  • Table 16: Dulera pivotal trial data in asthma
  • Table 17: Dulera Phase IV trial in asthma
  • Table 18: Dulera sales for asthma in the US ($m), 2017-26
  • Table 19: Dupixent drug profile
  • Table 20: Dupixent Phase III data in asthma
  • Table 21: Dupixent Phase III trials in asthma
  • Table 22: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 23: Fasenra drug profile
  • Table 24: Fasenra Phase III trials in asthma
  • Table 25: Ongoing Phase III trials for Fasenra in asthma
  • Table 26: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 27: Flutiform drug profile
  • Table 28: Flutiform pivotal trial data in asthma
  • Table 29: Flutiform Phase III trials in asthma
  • Table 30: Flutiform sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
  • Table 31: Nucala drug profile
  • Table 32: Nucala pivotal trial data in asthma
  • Table 33: Nucala late-phase trial data in asthma
  • Table 34: Nucala Phase III trials in asthma
  • Table 35: Nucala sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 36: QVM149 drug profile
  • Table 37: QVM149 Phase III trials in asthma
  • Table 38: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
  • Table 39: Singulair drug profile
  • Table 40: Singulair pivotal trial data in asthma
  • Table 41: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 42: Spiriva drug profile
  • Table 43: Spiriva pivotal trial data in asthma
  • Table 44: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 45: Symbicort drug profile
  • Table 46: Symbicort pivotal trial data in asthma
  • Table 47: Symbicort late-phase trial data in asthma
  • Table 48: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 49: Trelegy Ellipta drug profile
  • Table 50: Trelegy Ellipta Phase III trials in asthma
  • Table 51: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 52: Xolair drug profile
  • Table 53: Xolair pivotal trial data in asthma
  • Table 54: Xolair late-phase trial data in asthma
  • Table 55: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 56: Physicians surveyed for the asthma primary research study, 2017
  • Table 57: ICD-10 codes associated with asthma
  • Table 58: Classification of asthma in patients aged ≥12 years who are not taking long-term control medications, by impairment and risk
  • Table 59: Classification of patients after asthma becomes well controlled, by lowest level of treatment required to maintain control
  • Table 60: Severity of diagnosed asthma patients in the US, Japan, and five major EU markets, by country (%), 2017
  • Table 61: Branded therapies available for asthma across the US, Japan, and five major EU markets
  • Table 62: Global Initiative for Asthma stepwise approach for adjusting treatment of asthma
  • Table 63: Percentage of respondents using each set of guidelines for treatment of asthma, by country (%)
  • Table 64: Management of asthma patients in the US, Japan, and five major EU markets, by country, disease severity, and type of healthcare professional (%)
  • Table 65: Percentage of patients lost to follow-up*, by severity and country (%)
  • Table 66: Proportion of annual prescriptions filled, by severity and country (%)
  • Table 67: Prescribing influences in the treatment of asthma in the US, Japan, and five major EU markets, by country (%)
  • Table 68: Expected patient switching to inhaled generics in the US, Japan, and five major EU markets, by device type (%)
  • Table 69: Treatment challenges in asthma
  • Table 70: Patient compliance with asthma treatments, by drug formulation and country (%)
  • Table 71: Sources used for the epidemiological analysis of diagnosed asthma in the US, Japan, and five major EU markets, by country
  • Table 72: Global Initiative for Asthma guidelines on severity
  • Table 73: 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 74: Age- and gender-specific 12-month diagnosed prevalent cases of asthma in the US, Japan, and five major EU markets, by country, 2016
  • Table 75: 12-month prevalent cases of asthma in the US, Japan, and five major EU markets, by severity and country, 2016
  • Table 76: Validation of Datamonitor Healthcare's asthma prevalence forecast estimates against benchmark estimates
  • Table 77: Profiled key marketed drugs for asthma
  • Table 78: Advair drug profile
  • Table 79: Advair Diskus pivotal trial data in asthma
  • Table 80: Advair HFA pivotal trial data in asthma
  • Table 81: Advair late-phase trial data in asthma
  • Table 82: Advair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 83: Breo Ellipta drug profile
  • Table 84: Breo Ellipta pivotal trial data in asthma
  • Table 85: Breo Ellipta late-phase trial data in asthma
  • Table 86: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 87: Cinqair drug profile
  • Table 88: Cinqair pivotal Phase III data in asthma
  • Table 89: Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017-26
  • Table 90: Dulera drug profile
  • Table 91: Dulera pivotal trial data in asthma
  • Table 92: Dulera Phase IV trial in asthma
  • Table 93: Dulera sales for asthma in the US ($m), 2017-26
  • Table 94: Fasenra drug profile
  • Table 95: Fasenra Phase III trials in asthma
  • Table 96: Ongoing Phase III trials for Fasenra in asthma
  • Table 97: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 98: Flutiform drug profile
  • Table 99: Flutiform pivotal trial data in asthma
  • Table 100: Flutiform Phase III trials in asthma
  • Table 101: Flutiform sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
  • Table 102: Nucala drug profile
  • Table 103: Nucala pivotal trial data in asthma
  • Table 104: Nucala late-phase trial data in asthma
  • Table 105: Nucala Phase III trials in asthma
  • Table 106: Nucala sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 107: Singulair drug profile
  • Table 108: Singulair pivotal trial data in asthma
  • Table 109: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 110: Spiriva drug profile
  • Table 111: Spiriva pivotal trial data in asthma
  • Table 112: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 113: Symbicort drug profile
  • Table 114: Symbicort pivotal trial data in asthma
  • Table 115: Symbicort late-phase trial data in asthma
  • Table 116: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 117: Xolair drug profile
  • Table 118: Xolair pivotal trial data in asthma
  • Table 119: Xolair late-phase trial data in asthma
  • Table 120: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 121: Marketed products and approved indications for asthma in the US, Japan, and five major EU markets
  • Table 122: Pivotal safety and efficacy clinical trials for late-stage pipeline candidates in asthma
  • Table 123: US pricing of key marketed drugs
  • Table 124: Asthma and chronic obstructive pulmonary disease spend by payers, 2014
  • Table 125: Top 10 asthma and chronic obstructive pulmonary disease drug spend by Express Scripts members
  • Table 126: Spend on the top three asthma and chronic obstructive pulmonary disease drugs by Medicare Part D beneficiaries, 2013
  • Table 127: Global Initiative for Asthma treatment guidelines
  • Table 128: Formulary placement of asthma drugs in selected commercial formularies
  • Table 129: Formulary placement of asthma drugs in the top five 2016 Medicare Part D formularies
  • Table 130: Formulary placement of asthma drugs in selected large Medicaid states' preferred drug lists
  • Table 131: CVS Caremark's and Express Scripts' formulary-excluded asthma drugs
  • Table 132: Express Scripts' TRICARE formulary placement of asthma drugs
  • Table 133: Prior authorization criteria for asthma drugs by major health insurers and pharmacy benefit managers
  • Table 134: Pricing premiums given to medicines that can demonstrate benefit over comparators
  • Table 135: Pricing of key marketed asthma drugs in Japan
  • Table 136: Price calculation methodologies for asthma drugs launched in Japan after 2008
  • Table 137: Annual treatment cost of asthma drugs in the five major EU markets
  • Table 138: Access controls for asthma medications in the five major EU markets
  • Table 139: Availability and substitutability of branded generic inhalers in the five major EU markets
  • Table 140: List price differential between branded ICS/LABAs and branded generics in the five major EU markets
  • Table 141: Market access levers impacting ICS/LABA generic inhaler uptake in the five major EU markets
  • Table 142: Transparency Committee's ASMR ratings and pricing implications
  • Table 143: Transparency Committee's SMR ratings and pricing implications
  • Table 144: Transparency Committee's assessment of asthma treatments
  • Table 145: G-BA assessment of key asthma therapy
  • Table 146: Reimbursement conditions for asthma treatments in Italy
  • Table 147: Local formulary decisions for asthma drugs
  • Table 148: Therapeutic positioning reports for asthma drugs in Spain
  • Table 149: Spain regional assessments of asthma drugs
  • Table 150: NICE assessments of key asthma therapies
  • Table 151: CCG formulary inclusions for key asthma drugs
  • Table 152: SMC decisions on key asthma therapies
  • Table 153: SIGN asthma treatment guidelines
  • Table 154: Price sources and calculations for the US
  • Table 155: Price sources and calculations for the EU
  • Table 156: Exchange rates used for calculating branded drug prices
  • Table 157: Late-phase pipeline products in development for asthma
  • Table 158: Dupixent drug profile
  • Table 159: Dupixent Phase III data in asthma
  • Table 160: Dupixent Phase III trials in asthma
  • Table 161: Dupixent sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 162: QVM149 drug profile
  • Table 163: QVM149 Phase III trials in asthma
  • Table 164: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
  • Table 165: Trelegy Ellipta drug profile
  • Table 166: Trelegy Ellipta Phase III trials in asthma
  • Table 167: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Back to Top